An interventional study of Active repetitive transcranial magnetic stimulation and Sham repetitive transcranial magnetic stimulation in Peripheral Neuropathy, sponsored by Jakub Antczak. Recruiting at 1 site in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-10.
Sponsored by Jakub Antczak · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Neuralgia with a site in Poland — 4 open to participants now, 5 under way, none of them phase 3. Neuralgia · Poland.
Among the 27 studies in Neuralgia with a site in Poland, this one is the 23rd largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2022, is one of 5 with no phase, and was the 21st registered.
1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.
Browse Neuralgia studies →4 of the 27 studies in Neuralgia with a site in Poland are open now. Recruiting first, the newest first:
Centre of Postgraduate Medical Education · Sites in Poland
Ages 18+ · Men only
Pawel Sokal · Sites in Poland
Ages 18–80
Medical University of Warsaw · Sites in Poland
Ages 18+
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 155 Neuralgia studies recruiting now, 79 (51%) set no upper age limit and 44 (28%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 13 · Phase 3 4 · Phase 4 4
First in 2004; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 70 is above the median of 52 across 833 interventional studies indexed under Neuralgia.
Median enrollment 142 across the 25 interventional studies, 350 across the 2 observational. Of the 21 that completed or were terminated, 9 (43%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 27 have an industry lead sponsor. The 10 most frequent:
Jakub Antczak is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
Jakub Antczak has 1 study filed under Neuralgia — fewer than ten, so there is no comparison to draw.
1 of the studies in Neuralgia with a site in Poland that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07925060Medical University of WarsawUse of Transcutaneous Electrical Nerve Stimulation (TENS) in the Treatment of Pain Syndromes in Patients With Lower Limb Ischemia | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 27 studies in Neuralgia with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Peripheral neuropathy is a frequent condition, commonly associated with pain. Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity and is regarded as one of alternative methods to alleviate pain associated with various kind of neuropathies. rTMS is usually performed once a day and the whole therapy of neuropathic pain lasts one week. In a number of recent clinical trials including patients with depression and some other disorders, rTMS was delivered several times a day, which reduced the time of the whole therapy. This approach was termed an accelerated rTMS. The purpose of this study is to investigate feasibility of accelerated rTMS in treatment of neuropathic pain.
Peripheral neuropathy is a frequent condition, commonly associated with pain, which is often drug resistant. Repetitive Transcranial Magnetic Stimulation (rTMS) is a noninvasive method of modulation of brain plasticity. In this method, series of magnetic stimuli are delivered to the cerebral cortex, where they turn to electric current and depolarize repetitively the targeted neurons. If the stimulation is repeated during subsequent days it is capable to modify the activity of targeted cortical area for weeks or even months and by this way to achieve therapeutic effect. rTMS is most commonly used to treat drug-resistant depression but a number of other psychiatric and neurologic conditions is increasingly being regarded as therapeutic indication for rTMS. In patients suffering from neuropathic pain rTMS is delivered with high frequency, over primary motor areas (PMA). Stimulation of PMA should result in modulation of thalamic activity, achieved by antidromic excitation of thalamocortical connections. rTMS is usually performed once a day and the whole therapy of neuropathic pain lasts one week. In a number of recent clinical trials including patients with depression and some other disorders, rTMS was delivered several times a day, which reduced the time of the whole therapy. This approach was termed an accelerated rTMS. The purpose of this study is to investigate feasibility of accelerated rTMS in treatment of neuropathic pain.
1,103 studies on the registry are indexed under Neuralgia; 243 are open to participants now.
This study's planned enrollment of 70 is above the median of 52 across 833 interventional studies indexed under Neuralgia.
Browse Neuralgia studies →Jakub Antczak is the lead sponsor of 8 studies on the registry; 5 are open to participants now.
Compared within Neuralgia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Peripheral Nervous System Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
10 hertz (Hz) rTMS will be administered over the primary motor area. Therapy will include 6 sessions (three sessions in two consecutive days). In every sessions 1500 magnetic pulses of 90% of the resting motor threshold intensity will be elicited.
Device: Active repetitive transcranial magnetic stimulation
Sham stimulation will mimic the active one except that the stimulating coil will be held perpendicularly to the scalp, which assures similar impression as the active stimulation but prevents that significant magnetic field will reach brain tissue.
Device: Sham repetitive transcranial magnetic stimulation
High frequency rTMS over the primary motor area to induce the long term potentiation of primary motor areas for the muscles of upper extremity.
Sham stimulation to mimic the high frequency rTMS over the primary motor area.
Visual Analogue Scale of Pain Severity after rTMS
An analog scale of the length of 100 millimeter. Total score of 100, with higher scores representing more severe pain. Change from baseline score in the Visual Analogue Scale to the measurement taken after finishing rTMS.
Time frame: Through study completion, an average of 1 year.
Visual Analogue Scale of Pain Severity First Follow-up
An analog scale of the length of 100 millimeter. Total score of 100, with higher scores representing more severe pain. Change from baseline score in the Visual Analogue Scale to the measurement taken after two weeks after finishing rTMS.
Time frame: Before rTMS, up to one day after finishing rTMS.
Visual Analogue Scale of Pain Severity Second Follow-up
An analog scale of the length of 100 millimeter. Total score of 100, with higher scores representing more severe pain. Change from baseline score in the Visual Analogue Scale to the measurement taken after four weeks after finishing rTMS.
Time frame: Before rTMS, four weeks after finishing rTMS.
Numeric Pain Severity Scale after rTMS
Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken after finishing rTMS.
Time frame: Before rTMS, up to one day after finishing rTMS.
Numeric Pain Severity Scale First Follow-up
Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken two weeks after finishing rTMS.
Time frame: Before rTMS, two weeks after finishing rTMS.
Numeric Pain Severity Scale Second Follow-up
Total score 10, with higher scores representing more severe pain. Change from baseline score in the Numeric Pain Severity Scale to the measurement taken after four weeks after finishing rTMS.
Time frame: Before rTMS, four weeks after finishing rTMS.
Neuropathic Pain Symptoms Inventory after rTMS
Total score 120, with higher scores representing more severe pain and other symptoms of neuropathy. Change from baseline score in the Neuropathic Pain Symptoms Inventory to the measurement taken after finishing rTMS.
Time frame: Before rTMS, up to one day after finishing rTMS.
Neuropathic Pain Symptoms Inventory First Follow-up
Total score 120, with higher scores representing more severe pain and other symptoms of neuropathy. Change from baseline score in the Neuropathic Pain Symptoms Inventory to the measurement taken two weeks after finishing rTMS.
Time frame: Before rTMS, two weeks after finishing rTMS.
Neuropathic Pain Symptoms Inventory Second Follow-up
Total score 120, with higher scores representing more severe pain and other symptoms of neuropathy. Change from baseline score in the Neuropathic Pain Symptoms Inventory to the measurement taken four weeks after finishing rTMS.
Time frame: Before rTMS, four weeks after finishing rTMS.
Athens Insomnia Scale after rTMS
Total score 24, with higher scores representing more severe insomnia. Change from baseline score in the Athens Insomnia Scale to the measurement taken after finishing rTMS.
Time frame: Before rTMS, up to one day after finishing rTMS.
Athens Insomnia Scale First Follow-up
Total score 24, with higher scores representing more severe insomnia. Change from baseline score in the Athens Insomnia Scale to the measurement taken two weeks after finishing rTMS.
Time frame: Before rTMS, two weeks after finishing rTMS.
Athens Insomnia Scale Second Follow-up
Total score 24, with higher scores representing more severe insomnia. Change from baseline score in the Athens Insomnia Scale to the measurement taken four weeks after finishing rTMS.
Time frame: Before rTMS, four weeks after finishing rTMS.
Bilateral Dynamometric Assessment of the strength of the foot extension after rTMS
Change from baseline strength of the foot extension to the measurement taken after finishing rTMS.
Time frame: Before rTMS, up to one day after finishing rTMS.
Bilateral Dynamometric Assessment of the strength of the foot extension First Follow-up
Change from baseline strength of the foot extension to the measurement taken two weeks after finishing rTMS.
Time frame: Before rTMS, two weeks after finishing rTMS.
Bilateral Dynamometric Assessment of the strength of the foot extension Second Follow-up
Change from baseline strength of the foot extension to the measurement taken four weeks after finishing rTMS.
Time frame: Before rTMS, four weeks after finishing rTMS.
Plan to share: Yes — After completing the study, the age and gender of participants as well as the scores and results of all outcome measurements made at baseline, after rTMS, at the first and at the second follow-up will be made available to other researchers on request.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: The data will become available after the study results will be published.
Access criteria: On request sent by e-mail to jakub.antczak@uj.edu.pl
No publications or documents are linked to this record.
Started Nov 2022 (actual). Primary completion is estimated for Mar 2026, 40 months after the start.
Of 249 non-industry interventional studies with no phase under Neuralgia, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 41. This study's planned 40 months is above that.
Counting every sponsor, half of 267 studies reached it within 24 months; a quarter within 10 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jakub Antczak